TEVA, US8816242098

Teva stock at USD 41.10 below its USD 42.02 52-week high

Published on 10/12/2026 at 13:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Teva stock stood at USD 41.10 on October 9, 2026, versus USD 39.25. Volume reached 14.82 million shares against a 5.43 million average.

Key points in brief

Teva stock closed at USD 41.10 on October 9, 2026, below its USD 42.02 52-week high.
The NYSE quotation had a USD 47.9 billion market capitalization and a 68.6 P/E ratio.
Teva is scheduled to report third-quarter 2026 results on November 3, 2026.

TEVA, US8816242098, Illustration mit AI erstellt.

Teva Pharmaceutical Industries stock (ISIN US8816242098) closed at USD 41.10 on the NYSE on October 9, 2026, versus USD 39.25 at the preceding close. The quotation remained below its USD 42.02 52-week high, leaving the recent peak as the clearest market reference for the report.

Price remains near yearly high

The USD 41.10 close stood well above the USD 18.83 52-week low. Market capitalization was USD 47.9 billion as of October 9, 2026, while trading volume reached 14.82 million shares against a 5.43 million average.

The valuation snapshot was demanding on the reported market measures: Teva carried a P/E ratio of 68.6. The same quotation data showed a broad annual range from USD 18.83 to USD 42.02, placing the October 9 close near the top of that interval.

Comparison with peers

Teva: , P/E 68.6, market capitalization USD 47.9 billion

Viatris (NYSE, USD): plus 1.2 percent, P/E minus 49.0, market capitalization USD 20.5 billion

Sandoz (SIX, USD): plus 0.3 percent, P/E 56.6, market capitalization USD 36.5 billion

Next results arrive November 3

Teva's next scheduled reporting date is November 3, 2026, when the company is set to publish third-quarter 2026 results. Simply Wall St lists the release date and identifies Teva as a pharmaceutical and biotechnology company operating across the United States, Europe, Israel and other markets.

MarketWatch identifies Teva's primary listing as the NYSE and reports the October 9 close at USD 41.10, with a session high of USD 42.02 and a session low of USD 40.12.

Trading reference for investors

The completed NYSE session provides the latest dated home-market reference before the next U.S. session. Teva's USD 41.10 close, USD 47.9 billion market capitalization and 68.6 P/E ratio give investors three distinct measures for assessing the stock ahead of the November 3 results date.